The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA approved two anti-amyloid immunotherapies, lecanemab and donanemab, for “early-stage” AD, encompassing both stage 3 (MCI) and stage 4 (mild dementia).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [18]
In the citing paper
“Degeneration of cholinergic neurons is known to significantly contribute to cognitive decline in AD patients [132] and has been studied in a variety of genetic AD mouse models.”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [132]
In the citing paper
“AChE contributes to acetylcholine depletion and may facilitate the formation of neurotoxic Aβ-AChE complexes38.”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [38]
In the citing paper
“Cholinergic deficit also alters the permeability of the blood brain barrier causing erroneous transportation of metabolites and hampering the removal of amyloid plaque, worsening the disease condition [8].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [8]
In the citing paper
“From this point of view, AD could be prevented or effectively treated by decreasing the production of Aβ and tau; preventing aggregation or misfolding of these proteins; neutralizing or removing the toxic aggregate or misfolded forms of these proteins; or a combination of these modalities.7”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [7]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Research works printed but not linked: 1
- Geula, 1994, Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, 263
Cited by
Items 601–700 of 1,002
Cholinergic Modulation of General Anesthesia
Leung, L.-W. S., & Luo, T. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210421095504 · Cited by 19
Ni, R. (2021) · Pharmaceuticals · doi:10.3390/ph14111179 · Cited by 18
Systems biology of Alzheimer’s Disease: a scoping review of key pathways and mechanisms
Bice, P. J., Nho, K. T., Ertekin‐Taner, N., & Saykin, A. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00934-4 · Cited by 18
Hou, Z., Yu, M., Lu, K., Ma, Y., Jia, R., Lai, G., Bai, Y., & Huang, W. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70950 · Cited by 19
Pramanik, R., Dey, A., Chakrabarty, A. K., Banerjee, D., Narwaria, A., Sharma, S. K., Rai, R. K., Katiyar, C. K., & Dubey, S. K. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118402 · Cited by 18
Mechanism of Metal Complexes in Alzheimer’s Disease
Yi, L. I. U., Ma, J., Zhang, Q., Wang, Y., & Sun, Q. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211873 · Cited by 18
Autonomic nervous system flexibility for understanding brain aging
Lin, F. V., & Heffner, K. L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102016 · Cited by 18
Role of angiotensin receptor blockers in the context of Alzheimer's disease
Kuber, B., Fadnavis, M., & Chatterjee, B. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12872 · Cited by 18
Pak, M. E., Park, Y. J., Yang, H. J., Hwang, Y., Li, W., & Go, Y. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.153997 · Cited by 18
Semantic processing and neurobiology in Alzheimer's disease and Mild Cognitive Impairment
Almeida, V. N., & Radanovic, M. (2022) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2022.108337 · Cited by 18
Dubey, R., Lohidasan, S., Sankaran, S., & Arulmozhi, S. (2023) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2023.11.005 · Cited by 18
New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer’s Disease
Bon, L., Banaś, A., Dias, I., Melo-Marques, I., Cardoso, S. M., Chaves, S., & Santos, M. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020281 · Cited by 18
Abbas, S., Latif, M. S., Shafie, N. S., Ghazali, M. I., Abidin, N. A. Z., Mustafa, M. K., & Kormin, F. B. (2021) · Food Research · doi:10.26656/fr.2017.5(2).355 · Cited by 18
Lee, H. S., Kim, J. M., Lee, H. L., Go, M. J., Lee, D. Y., Kim, C. W., Kim, H., & Heo, H. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074063 · Cited by 18
Samad, N., Rafeeque, M., & Imran, I. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01143-w · Cited by 18
Lakra, N., Matore, B. W., Banjare, P., Singh, R. K., Singh, J., & Roy, P. P. (2022) · In Silico Pharmacology · doi:10.1007/s40203-022-00133-1 · Cited by 18
Mamun, A. A., Pidaný, F., Hulcová, D., Maříková, J., Kučera, T., Schmidt, M., Catapano, M. C., Hrabinová, M., Jun, D., Múčková, Ľ., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158308 · Cited by 18
He, L., Wang, X., Zhao, J., & Lin, Z. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105385 · Cited by 18
Szczurowska, E., Szánti‐Pintér, E., Chetverikov, N., Randáková, A., Kudová, E., & Jakubík, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010507 · Cited by 18
Caunca, M. R., Siedlecki, K. L., Cheung, Y. K., Alperin, N. J., Lee, S. H., Elkind, M. S. V., Sacco, R. L., Wright, C. B., & Rundek, T. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz279 · Cited by 18
Nishal, S., Phaugat, P., Bazaad, J., Dhaka, R., Khatkar, S., Khatkar, A., Khayatkashani, M., Alizadeh, P., Haghighi, S. M., Mehri, M., et al. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220614110616 · Cited by 18
Gyebi, G. A., Ogunyemi, O. M., Ibrahim, I. M., Ogunro, O. B., Afolabi, S. O., Johnson, O. R., Anyanwu, G. O., Batiha, G. E., & Adebayo, J. O. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10658-y · Cited by 18
Ajala, A., Uzairu, A., Shallangwa, G. A., & Abechi, S. E. (2023) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2023.102615 · Cited by 18
Şenol, F. S., Eren, G., Orhan, İ. E., Şener, B., Özgen, U., Aldaba, R., & Çalış, İ. (2021) · Molecules · doi:10.3390/molecules26072024 · Cited by 18
Zhang, W., Lv, M., Shi, Y., Mu, Y., Yao, Z.-Y., & Yang, Z. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6480381 · Cited by 18
Role of Interaction between Zinc and Amyloid Beta in Pathogenesis of Alzheimer’s Disease
Kozin, S. A. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923140055 · Cited by 17
Advance and Prospect of Positron Emission Tomography in Alzheimer’s disease research
Wang, Y., Liao, W., Wang, L., Li, J., Huang, D., Cheng, W., Tian, J., & Luan, P. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03081-2 · Cited by 17
Bubeníková, A., Procházka, V., Vacínek, D., Haratek, K., Skalický, P., Laczó, M., Laczó, J., Vlasák, A., Leško, R., Mládek, A., et al. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-336076 · Cited by 17
Laghchioua, F., Silva, C. F. M., Pinto, D. C. G. A., Cavaleiro, J. A. S., Mendes, R. F., Paz, F. A. A., Faustino, M. A. F., Rakib, E. M., Neves, M. G. P. M. S., Pereira, F., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00241 · Cited by 17
Reid, G. A., & Darvesh, S. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111012 · Cited by 17
Raghuvanshi, R., Nuthakki, V. K., Singh, L., Singh, B., Bharate, S. S., Bhatti, R., & Bharate, S. B. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153659 · Cited by 17
Cantone, A. F., Burgaletto, C., Benedetto, G. D., Pannaccione, A., Secondo, A., Bellanca, C. M., Augello, E., Munafò, A., Tarro, P., Bernardini, R., et al. (2024) · Cells · doi:10.3390/cells13040309 · Cited by 17
Brain insulin signaling and cognition: Possible links
Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2023) · EXCLI journal · doi:10.17179/excli2023-5841 · Cited by 17
Shukla, M., Wongchitrat, P., & Govitrapong, P. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03530-2 · Cited by 17
Ahmad, W., Choe, K., Ahmad, R., Park, T. J., & Kim, M. O. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1607289 · Cited by 17
Orciani, C., Hall, H., Pentz, R., Foret, M. K., Carmo, S. D., & Cuello, A. C. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15683 · Cited by 17
Self-citationTallino, S., Winslow, W., Bartholomew, S. K., & Velázquez, R. (2022) · Aging Cell · doi:10.1111/acel.13590 · Cited by 17
Prajapat, M., Kaur, G., Choudhary, G. P., Pahwa, P., Bansal, S., Joshi, R., Batra, G., Mishra, A., Singla, R., Kaur, H., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1296919 · Cited by 17
Singh, M., Jindal, D., Kumar, R., Pancham, P., Haider, S., Gupta, V., Mani, S., Rachana, R., Tiwari, R. K., & Chanda, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221222 · Cited by 17
Peřinová, R., Maafi, N., Korábečný, J., Kohelová, E., Simone, A. D., Mamun, A. A., Hulcová, D., Marková, J., Kučera, T., Jun, D., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103928 · Cited by 17
Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases
Mahmoudi, R., Novella, J., Badr, S., Boulahrouz, S., Tran, D. D., Morrone, I., & Jaïdi, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086921 · Cited by 17
Mu, R.-H., Tang, S., Han, X., Wang, H., Yuan, D., Zhao, J., Long, Y., & Hong, H. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110882 · Cited by 17
Sousa, G. L. S., Nadur, N. F., Ferreira, L. A., Honório, T. D. S., Simon, A., Cabral, L. M., Santos, M. L. M., Andrade, B., de Lima, E. V., Clarke, J. R., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117030 · Cited by 17
Dimkovski, A., Dobričić, V., Simić, M. R., Pavlova, M. J., Mihajloska, E., Sterjev, Z., & Panovska, A. P. (2025) · Molecules · doi:10.3390/molecules30102121 · Cited by 17
Pyun, J., Ryoo, N., Park, Y. H., & Kim, S. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00749-5 · Cited by 17
New Coumarin Derivatives as Cholinergic and Cannabinoid System Modulators
Montanari, S., Allarà, M., Scalvini, L., Kostrzewa, M., Belluti, F., Gobbi, S., Naldi, M., Rivara, S., Bartolini, M., Ligresti, A., et al. (2021) · Molecules · doi:10.3390/molecules26113254 · Cited by 17
Morroni, F., Sita, G., Graziosi, A., Ravegnini, G., Molteni, R., Paladini, M. S., Dias, K. S. T., dos Santos, A. F., Viegas, C., Camps, I., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00658 · Cited by 17
Andrews, J. F. V., Selvaraj, D. B., Kumar, A., Roshan, S. A., Anusuyadevi, M., & Kandasamy, M. (2023) · Brain Sciences · doi:10.3390/brainsci13071108 · Cited by 17
Shin, E., Lee, S. H., Sharma, N., Nguyen, B. T., Chung, Y. H., Kang, S. W., Nah, S.-Y., Lee, Y. J., Nabeshima, T., Jeong, J. H., et al. (2020) · Free Radical Research · doi:10.1080/10715762.2020.1854455 · Cited by 17
de Mello, J. E., Luduvico, K. P., dos Santos, A., Teixeira, F. C., Cardoso, J. D. S., Soares, M. S. P., Cunico, W. J., Vizzotto, M., Stefanello, F. M., & Spanevello, R. M. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01175-w · Cited by 17
Papagiouvannis, G., Theodosis‐Nobelos, P., & Rekka, E. A. (2024) · Molecules · doi:10.3390/molecules29163763 · Cited by 17
Batool, S., Furqan, T., Mahmood, M. S. H., Tweedie, D., Kamal, M. A., & Greig, N. H. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00200 · Cited by 17
Torreya grandis oil attenuates cognitive impairment in scopolamine-induced mice
Ma, J., Yuan, T., Gao, Y.-Q., Zeng, X., Liu, Z., & Gao, J. (2023) · Food & Function · doi:10.1039/d3fo03800a · Cited by 17
de Oliveira, F. F., de Almeida, S. S., Chen, E., Smith, M. D. A. C., & Bertolucci, P. H. F. (2022) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.21060160 · Cited by 17
Homolak, J., Perhoč, A. B., Knezović, A., Barilar, J. O., & Šalković‐Petrišić, M. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00637-9 · Cited by 17
Khatabi, K. E., Aanouz, I., El-Mernissi, R., Singh, A. K., Ajana, M. A., Lakhlifi, T., Kumar, S., & Bouachrıne, M. (2021) · TURKISH JOURNAL OF CHEMISTRY · doi:10.3906/kim-2010-34 · Cited by 17
Yu, P., Dong, W.-P., Tang, Y., Chen, H., Cui, Y., & Bian, X. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8093 · Cited by 17
Yu, M., Liu, S.-N., Luo, E.-E., Jin, Q., Liu, H., Liu, H., Luo, X., & Qin, X. (2022) · Phytochemistry · doi:10.1016/j.phytochem.2022.113394 · Cited by 17
Moss, D. E., & Perez, R. G. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241289602 · Cited by 16
Zou, Y., Guo, Q., Chang, Y., Jia, L., Zhai, L., Bai, Y., Sun, Q., & Wei, W. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113394 · Cited by 16
Teitsdottir, U. D., Darreh‐Shori, T., Lund, S. H., Jónsdóttir, M. K., Snædal, J., & Petersen, P. H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.876019 · Cited by 16
Ortiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 16
Kondak, C., Riedel, G., Harrington, C. R., Wischik, C. M., & Klein, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15553 · Cited by 16
The Potential of a Stratified Approach to Drug Repurposing in Alzheimer’s Disease
Anderson, C., Bucholc, M., McClean, P. L., & Zhang, S. (2023) · Biomolecules · doi:10.3390/biom14010011 · Cited by 16
Viel, C., Brandtner, A. T., Weißhaar, A., Lehto, A., Fuchs, M., & Klein, J. (2021) · Pharmaceuticals · doi:10.3390/ph14121218 · Cited by 16
Multifunctional Inhibitors of Cholinesterases for the Therapy of Alzheimer’s Disease (A Review)
Махаева, Г. Ф., & Бачурин, С. О. (2023) · Russian Journal of General Chemistry · doi:10.1134/s1070363223150161 · Cited by 16
Anupama, K. P., Antony, A., Olakkaran, S., Raghu, S. V., & Gurushankara, H. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02964-7 · Cited by 16
Araj‐Khodaei, M., Nouri, M., Farajdokht, F., Mohammadali, T., Kuchaksaray, F. R., Hamedyazdan, S., & Sadigh‐Eteghad, S. (2019) · Galen Medical Journal · doi:10.31661/gmj.v8i0.1559 · Cited by 16
Hosseini-Sharifabad, A., Rabbani, M., Seyed-Yousefi, Y., & Safavi, M. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.2.241 · Cited by 18
Calado, C. M. S. D. S., Manhães‐de‐Castro, R., Pereira, S. D. C., Souza, V. D. S., Barbosa, L. N. F., dos Santos, O. H., Lagranha, C. J., Juárez, P. A. R., Torner, L., Guzmán‐Quevedo, O., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03772-3 · Cited by 16
Qiu, T., Xie, F., Zeng, Q., Shen, Z., Du, G., Xu, X., Wang, C., Li, X., Luo, X., Li, K., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13852 · Cited by 16
Wang, D., Zheng, J., Sun, X., Xie, L., & Yang, Y. (2023) · Metabolites · doi:10.3390/metabo14010001 · Cited by 16
Lu, K., Xiong, X., Wang, X., & Wu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706762 · Cited by 16
Enhanced Recognition Memory through Dual Modulation of Brain Carbonic Anhydrases and Cholinesterases
Nocentini, A., Costa, A., Bonardi, A., Ammara, A., Giovannuzzi, S., Petreni, A., Bartolucci, G., Rani, B., Leri, M., Bucciantini, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01866 · Cited by 16
Yu, W.-Y., Low, I., Chen, C., Fuh, J., & Chen, L. (2021) · Entropy · doi:10.3390/e23040427 · Cited by 16
Wang, J., Shi, J., Jia, N., & Sun, Q. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03534-z · Cited by 16
Silva, C. F. M., Guerrinha, A. P. D. D. M. S., Carvalho, S., Pinto, D. C. G. A., & Silva, A. M. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030882 · Cited by 16
Association of cognitive enhancers and incident seizure risk in dementia: a population-based study
Ha, J.-H., Son, N., Park, Y. H., Lee, E. M., Kim, E., & Kim, W. J. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03120-5 · Cited by 16
Nazari, M., Rezaee, E., Hariri, R., Akbarzadeh, T., & Tabatabai, S. A. (2021) · EXCLI journal · doi:10.17179/excli2021-3569 · Cited by 16
Mechanistic insight of the potential of geraniol against Alzheimer’s disease
Liu, Y., Zhou, S., Huang, X., & Rehman, H. M. (2022) · European journal of medical research · doi:10.1186/s40001-022-00699-8 · Cited by 16
Cell-based therapy in Alzheimer's disease: can human fetal cholinergic neurons “untangle the skein”?
Guarnieri, G., Sarchielli, E., Vannelli, G. B., & Morelli, A. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.241459 · Cited by 16
Al-Karmalawy, A. A., Mohamed, A. F., Shalaby, H. N., Elmaaty, A. A., El‐Shiekh, R. A., Zeidan, M. A., Alnajjar, R. A., Alzahrani, A. Y. A., Mughram, M. H. A., Shaldam, M. A., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00778f · Cited by 16
Zhang, Y., Gu, X., Zhou, Y., Si, N., Gao, W., Bo, S., Sun, J., Li, T., Wang, L., Wei, X., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154527 · Cited by 16
Liu, Y., Tu, Y., Kang, Y., Zhu, C., Wu, C., Chen, G., Liu, Z., & Li, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-17912-7 · Cited by 16
Gyebi, G. A., Ejoh, J. C., Ogunyemi, O. M., Afolabi, S. O., Ibrahim, I. M., Anyanwu, G. O., Olorundare, O. E., Adebayo, J. O., & Koketsu, M. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01467-7 · Cited by 16
Effects of Long‐Term Exposure to L‐Band High‐Power Microwave on the Brain Function of Male Mice
Lin, Y., Gao, P., Guo, Y., Chen, Q., Lang, H., Guo, Q., Miao, X., Li, J., Zeng, L., & Guo, G. (2021) · BioMed Research International · doi:10.1155/2021/2237370 · Cited by 16
Zhang, H., Wu, C., Chen, X., Zhang, Z., Jiang, X., Qin, H., & Tang, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202100272 · Cited by 15
Tsolias, A., & Medalla, M. (2022) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.795325 · Cited by 15
Chen, Q., Chen, F., Long, C., Zhu, Y., Jiang, Y., Zhu, Z., Lu, J., Zhang, X., Nedelská, Z., Hort, J., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01233-6 · Cited by 15
The potential link between the development of Alzheimer’s disease and osteoporosis
Nasme, F., Behera, J., Tyagi, P., Debnath, N., Falcone, J. C., & Tyagi, N. (2025) · Biogerontology · doi:10.1007/s10522-024-10181-z · Cited by 15
Li, P., He, Y., & He, M. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06454-y · Cited by 15
Gene therapy: an alternative to treat Alzheimer’s disease
Doshi, V., Joshi, G., Sharma, S., & Choudhary, D. K. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02873-z · Cited by 15
Benetik, S. F., Knez, D., Obreza, A., Košak, U., & Gobec, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108748 · Cited by 15
Shoukat, S., Zia, M. A., Uzair, M., Alsubki, R. A., Sajid, K., Shoukat, S., Attia, K. A., Fiaz, S., Ali, S., Kimiko, I., et al. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08674-0 · Cited by 15
The how and why of sleep: Motor theory and catecholamine hypothesis
Ma, C., & Dan, Y. (2025) · Neuron · doi:10.1016/j.neuron.2025.08.017 · Cited by 15
Advancing Nanomaterial-Based Strategies for Alzheimer’s Disease: A Perspective
Zhou, H., Yin, X., Zhang, G., Yang, Z., & Zhou, R. (2025) · JACS Au · doi:10.1021/jacsau.5c00002 · Cited by 15
Hypothesis on ontogenesis and pathophysiology of Alzheimer’s disease
Schwab, E. D. P., Queiroz, R., Fiebrantz, A. K. B., Bastos, M., Bonini, J. S., & da Silva, W. C. F. N. (2022) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2022rw0170 · Cited by 15
Ahnaou, A., White, E. R., Biermans, R., Manyakov, N. V., & Drinkenburg, W. H. I. M. (2020) · Neural Plasticity · doi:10.1155/2020/6249375 · Cited by 15
Kim, J. H., Han, Y., Oh, S., Lee, B., Kwon, O., Choi, C. W., & Kim, M. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-38773-8 · Cited by 15
Baidya, A. T. K., Goswami, A. K., Das, B., Darreh‐Shori, T., & Kumar, R. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00361 · Cited by 16
Metadata
- Authors
- Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Northwestern University (US)
- McGill University (CA)
- Indiana University School of Medicine (US)
- University Hospital of Geneva (CH)
- Saint Louis University (US)
- Prevent Alzheimer’s Disease 2020 (US)
- University of Rhode Island (US)
- Corresponding author
- Hampel, Harald
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-29
- Volume
- 141
- Issue
- 7
- Pages
- 1917-1933
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6022632
- OpenAlex
- W2805257646
- Cited by
- 1,918
- References
- 179
- Citations by year
- 2026: 245 · 2025: 298 · 2024: 298 · 2023: 328 · 2022: 300 · 2021: 228 · 2020: 130 · 2019: 65 · 2018: 21
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- AXA Research Fund
- ‘Fondation pour la Recherche sur Alzheimer’, Paris, France. Ce travail a bénéficié d'une aide de l’Etat ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- Canadian Institutes of Health Research
- National Research Council
- Alzheimer Society of Canada
- Rotary Club Livorno ‘Mascagni’/The Rotary Foundation (GG1758249)
- ADC (AG013854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic system, cholinergic hypothesis, cholinesterase inhibitors, acetylcholine, cholinergic denervation, neurofibrillary degeneration, amyloid plaques, cognitive decline, cholinergic drugs, combination therapy
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Humans, Amyloid beta-Peptides, Neurofibrillary Tangles, Cholinergic Agents, Cholinergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.